SuperworthHWH International ESYN
- Market cap
- $13.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 33.7×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $389.7K
- −69% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −7.3%
HWH International trades at 33.7× sales. Revenue was $389.7K over the last twelve months, down 69% on a year earlier.
Charts
Financials
| Income statement | Q4 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | $207.9K | $286.1K | $334.9K | $345.5K | $287.1K+38% | $295.2K+3% | $310.4K−7% | $206.8K−40% | $54.6K−81% | $64.2K−78% | $64.2K−79% | |
| Cost of revenue | n/a | $97K | $122.8K | $170K | $185.7K | $173.3K+79% | $147.6K+20% | $266.3K+57% | $83.2K−55% | $14.9K−91% | $16.9K−89% | $43.8K−84% |
| Gross profit | n/a | $110.9K | $163.3K | $164.9K | $159.9K | $113.8K+3% | $147.6K−10% | $44.1K−73% | $123.6K−23% | $39.7K−65% | $47.3K−68% | $20.4K−54% |
| SG&A | $583.7K | $1M | $1.1M | $654.7K | $487.4K−17% | $375.3K−63% | $664.2K−41% | $383.9K−41% | $325K−33% | $2.1M+447% | $672.2K+1% | $249.1K−35% |
| n/a | −$603.7K | −$887.9K | −$509.8K | −$701.9K | −$420.5K−30% | −$576.7K−35% | −$476.1K−7% | −$331.5K−53% | −$2.1M+391% | −$673.2K+17% | −$166.4K−65% | |
| Interest expense | n/a | n/a | $18.1K | $18.7K | $18.5K | $16.8K | $50.1K+177% | $29.5K+58% | $32.1K+74% | −$59.5K | $9.1K−82% | $2.3K−92% |
| Pre-tax income | −$183.8K | −$989.1K | −$1.3M | −$403.6K | −$537.1K+192% | −$329.2K−67% | −$531.2K−60% | $76K | −$295.1K−45% | −$1.9M+492% | −$626.8K+18% | $210.7K+177% |
| $47.2K | $40.4K | n/a | n/a | n/a | n/a | $42.9K | $0 | $4.5K | $0 | n/a | n/a | |
| Net income | −$231K | −$1M | −$1.3M | −$387.9K | −$548.5K+137% | −$317.5K−69% | −$565.1K−58% | $83.4K | −$291K−47% | −$1.9M+513% | −$626.2K+11% | $212K+154% |
| −$0.45 | n/a | n/a | n/a | n/a | n/a | −$0.09 | $0.01 | n/a | n/a | −$0.08−11% | $0.03+200% | |
| 490K | n/a | n/a | n/a | n/a | n/a | 6.4M | 6.5M | n/a | n/a | 7.5M+17% | 7.5M+16% |
Operating income: 14 periods, Q1 FY23 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY22 and Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest HWH International's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ESYNHWH International | $13.1M | n/m | n/a | 33.7× | −69% | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $64.6M | 13.6× | 14.8× | 1.1× | +6% | 4.9% |
More on HWH International
Each number over time
Where it ranks
Its groups
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .